

- American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009;19:1167–1214.
- Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. *J Clin Endocrinol Metab* 1955;15:1270–1280.
- Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. *Clin Endocrinol (Oxf)* 1977;7:481–493.
- Hegedus L. Clinical practice. The thyroid nodule. *N Engl J Med* 2004;351:1764–1771.
- Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. *Thyroid* 1998;8:989–995.
- Yassa L, Cibas ES, Benson CB, et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. *Cancer* 2007;111:508–516.
- Gharib H, Papini E, Valcavi R, et al. American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. *Endocr Pract* 2006;12:63–102.
- Corrias A, Einaudi S, Chiorboli E, et al. Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. *J Clin Endocrinol Metab* 2001;86:4644–4648.
- Schneider AB, Sarne DH. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. *Nat Clin Pract Endocrinol Metab* 2005;1:82–91.
- Boelaert K, Horacek J, Holder RL, et al. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *J Clin Endocrinol Metab* 2006;91:4295–4301.
- Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* 2006;154:787–803.
- Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. *J Clin Endocrinol Metab* 2006;91:3411–3417.
- Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. *Am J Med* 1992;93:363–369.
- Tan GH, Gharib H, Reading CC. Solitary thyroid nodule. Comparison between palpation and ultrasonography. *Arch Intern Med* 1995;155:2418–2423.
- Bisi H, de Camargo RY, Longatto Filho A. Role of fine-needle aspiration cytology in the management of thyroid nodules: review of experience with 1,925 cases. *Diagn Cytopathol* 1992;8:504–510.
- Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. *J Clin Endocrinol Metab* 2011;96:3390–3397.
- Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. *New Engl J Med* 2012;367:705–715.
- Tuttle RM, Ball DW, Byrd D, et al. Thyroid carcinoma. *J Natl Compr Canc Netw* 2010;8:1228–1274.
- Bogsrud TV, Karantanis D, Nathan MA, et al. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. *Nucl Med Commun* 2007;28:373–381.
- Cohen MS, Arslan N, Dehdashti F, et al. Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. *Surgery* 2001;130:941–946.
- Kang KW, Kim SK, Kang HS, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. *J Clin Endocrinol Metab* 2003;88:4100–4104.
- King DL, Stack BC Jr, Spring PM, et al. Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas. *Otolaryngol Head Neck Surg* 2007;137:400–404.
- Uematsu H, Sadato N, Ohtsubo T, et al. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. *J Nucl Med* 1998;39:453–459.
- Kresnik E, Gallowitsch HJ, Mikosch P, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. *Surgery* 2003;133:294–299.
- Are C, Hsu JF, Schoder H, et al. FDG-PET detected thyroid incidentalomas: need for further investigation? *Ann Surg Oncol* 2007;14:239–247.
- Yasuda S, Shohsuta A, Ide M, et al. Chronic thyroiditis: diffuse uptake of FDG at PET. *Radiology* 1998;207:775–778.
- Boerner AR, Voth E, Theissen P, et al. Glucose metabolism of the thyroid in Graves' disease measured by F-18-fluoro-deoxyglucose positron emission tomography. *Thyroid* 1998;8:765–772.
- Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. *J Clin Endocrinol Metab* 2001;86:5307–5312.
- Pedersen RK, Pedersen NT. Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study. *Histopathology* 1996;28:25–32.
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. *CA Cancer J Clin* 2009;59:225–249.
- Jossart GH, Clark OH. Well-differentiated thyroid cancer. *Curr Probl Surg* 1994;31:933–1012.
- Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. *Cancer Control* 2000;7:229–239.
- Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. *Surgery* 1987;102:1088–1095.
- Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. *Surgery* 1988;104:947–953.
- Hay ID, Bergstrahl EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. *Surgery* 1993;114:1050–1057; discussion 1057–1058.
- Hay ID. Papillary thyroid carcinoma. *Endocrinol Metab Clin North Am* 1990;19:545–576.
- Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. *J Clin Endocrinol Metab* 2003;88:5399–5404.
- Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. *Cancer Res* 2003;63:1454–1457.
- Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. *Cancer Res* 2003;63:4561–4567.
- Zhu Z, Ciampi R, Nikiforova MN, et al. Prevalence of RET/PTC rearrangements in thyroid papillary carcinomas: effects of the detection methods and genetic heterogeneity. *J Clin Endocrinol Metab* 2006;91:3603–3610.
- Namba H, Rubin SA, Fagin JA. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. *Mol Endocrinol* 1990;4:1474–1479.
- Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. *J Clin Oncol* 2009;27:2977–2982.
- Ito Y, Yoshida H, Maruo R, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. *Endocr J* 2009;56:89–97.
- Rivera M, Ricarte-Filho J, Tuttle RM, et al. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. *Thyroid* 2010;20:1085–1093.
- Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. *J Clin Endocrinol Metab* 2008;93:3943–3949.
- Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. *J Clin Endocrinol Metab* 2003;88:4393–4397.
- Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. *J Clin Endocrinol Metab* 2010;95:4197–4205.
- Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. *Surgery* 1995;118:1131–1136; discussion 1136–1138.
- Hay ID, Ryan JJ, Grant CS, et al. Prognostic significance of nondiploid DNA determined by flow cytometry in sporadic and familial medullary thyroid carcinoma. *Surgery* 1990;108:972–979; discussion 979–980.
- Carling T, Ocal IT, Udelsman R. Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer? *World J Surg* 2007;31:916–925.
- LiVolsi VA, Asa SL. The demise of follicular carcinoma of the thyroid gland. *Thyroid* 1994;4:233–236.
- Carling T, Udelsman R. Follicular neoplasms of the thyroid: what to recommend. *Thyroid* 2005;15:583–587.
- Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. *World J Surg* 2002;26:879–885.
- Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. *Surg Oncol Clin N Am* 1996;5:43–63.
- Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. *Trans Am Clin Climatol Assoc* 2002;113:241–260.

56. Jonklaas J, Sarlis NJ, Litofsky D, et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. *Thyroid* 2006;16:1229–1242.
57. Brierley J, Tsang R, Panzarella T, et al. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. *Clin Endocrinol (Oxf)* 2005;63:418–427.
58. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. *Br J Cancer* 2003;89:1638–1644.
59. Baloch ZW, LiVolsi VA. Microcarcinoma of the thyroid. *Adv Anat Pathol* 2006;13:69–75.
60. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. *Cancer* 1998;83:553–559.
61. Hay ID, Hutchinson ME, Gonzalez-Losada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. *Surgery* 2008;144:980–987; discussion 987–988.
62. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. *Thyroid* 2003;13:381–387.
63. Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. *BMJ* 2013;347:f4706.
64. Roman S, Sosa JA. Aggressive variants of papillary thyroid cancer. *Curr Opin Oncol* 2013;25:33–38.
65. Smallridge RC, Meek SE, Morgan MA, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. *J Clin Endocrinol Metab* 2007;92:82–87.
66. Brauckhoff M, Meinicke A, Bilkenroth U, et al. Long-term results and functional outcome after cervical esviceration in patients with thyroid cancer. *Surgery* 2006;140:953–959.
67. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab* 2006;91:2892–2899.
68. Clark OH, Hoelting T. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. *Thyroid* 1994;4:501–505.
69. Schlumberger MJ. Papillary and follicular thyroid carcinoma. *New Engl J Med* 1998;338:297–306.
70. Fatourechi V, Hay ID, Javedan H, et al. Lack of impact of radioiodine therapy in tg-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. *J Clin Endocrinol Metab* 2002;87:1521–1526.
71. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. *J Clin Endocrinol Metab* 2000;85:1107–1113.
72. Robbins RJ, Wan Q, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. *J Clin Endocrinol Metab* 2006;91:498–505.
73. van Dijk D, Plukker JT, Phan HT, et al. 18-fluorodeoxyglucose positron emission tomography in the early diagnostic workup of differentiated thyroid cancer patients with a negative post-therapeutic iodine scan and detectable thyroglobulin. *Thyroid* 2013;23:1003–1009.
74. Lebouilleux S, Schroeder PR, Schlumberger M, et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. *Nat Clin Pract Endocrinol Metab* 2007;3:112–121.
75. Livraghi T, Paracchi A, Ferrari C, et al. Treatment of autonomous thyroid nodules with percutaneous ethanol injection: preliminary results. Work in progress. *Radiology* 1990;175:827–829.
76. Lewis BD, Hay ID, Charboneau JW, et al. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. *AJR Am J Roentgenol* 2002;178:699–704.
77. Hay ID, Charboneau JW. The coming of age of ultrasound-guided percutaneous ethanol ablation of selected neck nodal metastases in well-differentiated thyroid carcinoma. *J Clin Endocrinol Metab* 2011;96:2717–2720.
78. Lim CY, Yun JS, Lee J, et al. Percutaneous ethanol injection therapy for locally recurrent papillary thyroid carcinoma. *Thyroid* 2007;17:347–350.
79. Kim BM, Kim MJ, Kim EK, et al. Controlling recurrent papillary thyroid carcinoma in the neck by ultrasonography-guided percutaneous ethanol injection. *Eur Radiol* 2008;18:835–842.
80. Heilo A, Sigstad E, Fagerlid KH, et al. Efficacy of ultrasound-guided percutaneous ethanol injection treatment in patients with a limited number of metastatic cervical lymph nodes from papillary thyroid carcinoma. *J Clin Endocrinol Metab* 2011;96:2750–2755.
81. Hay ID, Lee RA, Davidge-Pitts C, et al. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected “recurrent” neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and I therapy. *Surgery* 2014;154:1448–1454.
82. Anderson RT, Linnehan JE, Tongbram V, et al. Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review. *Thyroid* 2013;23:392–407.
83. Lebouilleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. *Lancet Oncol* 2012;13:897–905.
84. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. *Lancet Oncol* 2010;11:962–972.
85. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. *New Engl J Med* 2013;368:623–632.
86. Granata R, Locati L, Licitra L. Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature. *Curr Opin Oncol* 2013;25:224–228.
87. Smallridge RC. Approach to the patient with anaplastic thyroid carcinoma. *J Clin Endocrinol Metab* 2012;97:2566–2572.
88. Smallridge RC, Ain KB, Asa SL, et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. *Thyroid* 2012;22:1104–1139.
89. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. *Surgery* 2001;130:1028–1034.
90. Bogsrud TV, Karantanis D, Nathan MA, et al. 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. *Thyroid* 2008;18:713–719.
91. Ain KB, Egorin MJ, DeSimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. *Thyroid* 2000;10:587–594.
92. Higashiyama T, Ito Y, Hirokawa M, et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. *Thyroid* 2010;20:7–14.
93. Bhatia A, Rao A, Ang KK, et al. Anaplastic thyroid cancer: Clinical outcomes with conformal radiotherapy. *Head Neck* 2010;32:829–836.
94. Isham CR, Bossou AR, Negron V, et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. *Sci Transl Med* 2013;5:166ra3.
95. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. *Thyroid* 2010;20:975–980.
96. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. *Thyroid* 2009;19:233–240.
97. Hogan T, Jing Jie Yu, Williams HJ, et al. Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. *J Oncol Pharm Pract* 2009;15:111–117.
98. Masago K, Miura M, Toyama Y, et al. Good clinical response to erlotinib in a patient with anaplastic thyroid carcinoma harboring an epidermal growth factor somatic mutation, L858R, in exon 21. *J Clin Oncol* 2011;29:e465–e467.
99. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. *Thyroid* 2008;18:317–323.
100. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. *Thyroid* 2009;19:565–612.
101. Hundahl SA, Fleming ID, Fremgen AM, et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. *Cancer* 1998;83:2638–2648.
102. Pelizzo MR, Boschin IM, Bernante P, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. *Eur J Surg Oncol* 2007;33:493–497.
103. Wöhlk N, Cote GJ, Bugalho MM, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab* 1996;81:3740–3745.
104. Zedenius J, Wallin G, Hamberger B, et al. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTCs. *Hum Mol Genet* 1994;3:1259–1262.
105. Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. *Clin Endocrinol* 1995;43:123–127.
106. Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. *J Clin Endocrinol Metab* 2007;92:4725–4729.
107. Pacini F, Castagna MG, Cipri C, et al. Medullary thyroid carcinoma. *Clin Oncol (R Coll Radiol)* 2010;22:475–485.
108. Brandi ML, Gagel RF, Angelini A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* 2001;86:5658–5671.
109. Farndon JR, Leight GS, Dillew W, et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. *Br J Surg* 1986;73:278–281.
110. Machens A, Dralle H. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside. *Mol Cell Endocrinol* 2006;247:34–40.
111. Machens A, Gimm O, Hinze R, et al. Genotype-phenotype correlations in hereditary medullary thyroid carcinoma: oncological features and biochemical properties. *J Clin Endocrinol Metab* 2001;86:1104–1109.
112. Trimboli P, Nasrollah N, Amendola S, et al. Should we use ultrasound features associated with papillary thyroid cancer in diagnosing medullary thyroid cancer? *Endocr J* 2012;59:503–508.
113. Choi N, Moon WJ, Lee JH, et al. Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results. *Acta Radiol* 2011;52:312–316.

114. Lee S, Shin JH, Han BK, et al. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. *AJR Am J Roentgenol* 2010;194:1090–1094.
115. Kim SH, Kim BS, Jung SL, et al. Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. *Korean J Radiol* 2009;10:101–105.
116. Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. *J Surg Oncol* 2005;91:56–60.
117. Bhanot P, Yang J, Schnadig VJ, et al. Role of FNA cytology and immunohistochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature. *Diagn Cytopathol* 2007;35:285–292.
118. Moley JF. Medullary thyroid carcinoma. *Curr Treat Options Oncol* 2003;4:339–347.
119. Modigliani E, Cohen R, Campos JM, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs a calcitonine. *Clin Endocrinol (Oxf)* 1998;48:265–273.
120. Tisell LE, Hansson G, Jansson S, et al. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. *Surgery* 1986;99:60–66.
121. Moley JF, Wells SA, Dilley WG, et al. Reoperation for recurrent or persistent medullary thyroid cancer. *Surgery* 1993;114:1090–1095; discussion 1095–1096.
122. Fialkowski E, DeBenedetti M, Moley J. Long-term outcome of reoperations for medullary thyroid carcinoma. *World J Surg* 2008;32:754–765.
123. van Veelen W, de Groot JW, Acton DS, et al. Medullary thyroid carcinoma and biomarkers: past, present and future. *J Intern Med* 2009;266:126–140.
124. Ong SC, Schöder H, Patel SG, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. *J Nucl Med* 2007;48:501–507.
125. Barbet J, Campion L, Kraeber-Bodéré F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. *J Clin Endocrinol Metab* 2005;90:6077–6084.
126. Laure Giraudet A, Al Ghulzan A, Aupérin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. *Eur J Endocrinol* 2008;158:239–246.
127. Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. *Thyroid* 1996;6:305–310.
128. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. *J Clin Oncol* 2012;30:134–141.
129. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. *J Clin Oncol* 2013;31:3639–3646.
130. Graff-Baker A, Sosa JA, Roman SA. Primary thyroid lymphoma: a review of recent developments in diagnosis and histology-driven treatment. *Curr Opin Oncol* 2010;22:17–22.
131. Skarsgard ED, Connors JM, Robins RE. A current analysis of primary lymphoma of the thyroid. *Arch Surg* 1991;126:1199–1203; discussion 1203–1204.
132. Ota H, Ito Y, Matsuzuka F, et al. Usefulness of ultrasonography for diagnosis of malignant lymphoma of the thyroid. *Thyroid* 2006;16:983–987.
133. Junor EJ, Paul J, Reed NS. Primary non-Hodgkin's lymphoma of the thyroid. *Eur J Surg Oncol* 1992;18:313–321.
134. Tsang RW, Gospodarowicz MK, Sutcliffe SB, et al. Non-Hodgkin's lymphoma of the thyroid gland: prognostic factors and treatment outcome. The Princess Margaret Hospital Lymphoma Group. *Int J Radiat Oncol Biol Phys* 1993;27:599–604.
135. Tupchong L, Hughes F, Harmer CL. Primary lymphoma of the thyroid: clinical features, prognostic factors, and results of treatment. *Int J Radiat Oncol Biol Phys* 1986;12:1813–1821.
136. Graff-Baker A, Roman SA, Thomas DC, et al. Prognosis of primary thyroid lymphoma: demographic, clinical, and pathologic predictors of survival in 1,408 cases. *Surgery* 2009;146:1105–1115.
137. Friedberg MH, Coburn MC, Monchik JM. Role of surgery in stage IE non-Hodgkin's lymphoma of the thyroid. *Surgery* 1994;116:1061–1066; discussion 1066–1067.
138. Pyke CM, Grant CS, Habermann TM, et al. Non-Hodgkin's lymphoma of the thyroid: is more than biopsy necessary? *World J Surg* 1992;16:604–609; discussion 609–610.
139. Hung W, Sarlis NJ. Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. *Thyroid* 2002;12:683–702.
140. Hogan AR, Zhuge Y, Perez EA, et al. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. *J Surg Res* 2009;156:167–172.
141. Zimmerman D, Hay ID, Gough IR, et al. Papillary thyroid carcinoma in children and adults: long-term follow-up of 1039 patients conservatively treated at one institution during three decades. *Surgery* 1988;104:1157–1166.
142. Harness JK, Thompson NW, McLeod MK, et al. Differentiated thyroid carcinoma in children and adolescents. *World J Surg* 1992;16:547–553; discussion 553–554.
143. Hay ID, Gonzalez-Losada R, Reinalda MS, et al. Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008. *World J Surg* 2010;34:1192–1202.